VMAT

V-Square Announces Liquidation of Exchange Traded Funds

Retrieved on: 
Wednesday, December 13, 2023
Finance, Banking, Professional Services, Other Professional Services, Asset Management, Carbon, ETF, Risk, VMAT, NYSE, NAV, Fund, Materiality, Trustee, CBOE, Security (finance)

Each Fund's last day of trading will be January 9, 2024, which will also be the final day for creation unit orders by authorized participants.

Key Points: 
  • Each Fund's last day of trading will be January 9, 2024, which will also be the final day for creation unit orders by authorized participants.
  • Each Fund will conclude operations and distribute the remaining proceeds to shareholders promptly after the close of business January 10, 2024.
  • Shareholders who do not sell their Fund shares by this date will have their shares automatically redeemed for cash based on the Fund's net asset value (NAV).
  • Shareholders should contact their tax advisor to discuss the income tax consequences of the liquidation.

Vejle Hospital becomes first center in the world to use RayStation for an online adaptive treatment with augmented CBCT

Retrieved on: 
Monday, November 20, 2023
Online, Gy, Acquisition, Teaching hospital, RaySearch Laboratories, CBCT, Workflow, Cancer, VMAT, Health, Pharmaceutical industry, Medical imaging

The improved workflow is enabled by the adaptive replanning capabilities of RayStation®* and significantly saves time for the patient.

Key Points: 
  • The improved workflow is enabled by the adaptive replanning capabilities of RayStation®* and significantly saves time for the patient.
  • Thanks to the synthetic CT algorithm and fast adaptive replanning capabilities in RayStation, the CBCT of the first treatment fraction can be used for creating an adapted plan during the treatment session.
  • In the current example, the online adaptation was motivated by differences in positioning at image acquisition and at treatment.
  • RayStation has very advanced tools available for taking online adaptive into clinical routine and the work done by Vejle is showcasing what groundbreakning possibilities our users have to further advance cancer treatments."

Establishment Labs Announces FDA Clearance of Motiva Flora SmoothSilk Tissue Expander

Retrieved on: 
Monday, October 16, 2023
Health, Medical Devices, Other Health, Artifact, Partnership, RFID, Earnings before interest, taxes, depreciation and amortization, Food, Google Images, Metal, Breast cancer, Inflammation, Breast, Radiology, Breast pain, Michelle Brunner, Heart, VMAT, Radiation, Motiva, University, FDA, Applied science, Rabbit, CT, Magnet, Environment, Luigi Cozzi, Safety, History, Medicine, Mouse, MRI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Establishment, Human, Woman, Diversified Specialty Institute Holdings, Inc., Patient, Surgeon, ESTA, Pharmaceutical industry, Medical imaging, Omid Veiseh

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Motiva Flora® SmoothSilk® Tissue Expander.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Motiva Flora® SmoothSilk® Tissue Expander.
  • The Flora® SmoothSilk® Tissue Expander offers several proprietary innovations, including Establishment Labs’ patented SmoothSilk® surface technology.
  • By being magnet-free, Flora avoids the interference that magnets can cause during MRI and may improve the precision of radiation oncology treatment.
  • “This is an incredibly important day in the history of Establishment Labs, as the first of our implantable technologies has been approved by the FDA,” said Juan José Chacón-Quirós, Founder and Chief Executive Officer of Establishment Labs.

RayCare is interoperable with Varian TrueBeam

Retrieved on: 
Wednesday, May 24, 2023
RaySearch Laboratories, Electron, IMRT, Varian Medical Systems, OIS, VMAT, Medical examiner, Asset management, Varian

STOCKHOLM, May 24, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) is proud to announce that the oncology information system RayCare®* can connect to Varian TrueBeam® linear accelerators.

Key Points: 
  • STOCKHOLM, May 24, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) is proud to announce that the oncology information system RayCare®* can connect to Varian TrueBeam® linear accelerators.
  • This kind of bi-lateral connection is referred to as interoperability, and after an extensive program with joint development and testing, Varian has now certified that RayCare is interoperable with the TrueBeam platform.
  • This applies to all linacs in the TrueBeam family: TrueBeam, TrueBeam STx, Edge and VitalBeam.
  • Johan Löf, founder and CEO, RaySearch, says: "As previously communicated, achieving interoperability between RayCare and TrueBeam has taken longer than originally planned.

Sun Nuclear Showcases Evolving and Expanding Quality Management Portfolio at ESTRO 2023 Meeting

Retrieved on: 
Friday, May 12, 2023
GE HealthCare, CIRS, Clatterbridge Cancer Centre NHS Foundation Trust, User-centered design, Radiation, Quality management, GE, Emerging, EPID, Ultrasound, MR, Radiation therapy, Medical imaging, Motion, Gold, QA, MIR, IVD, Ecosystem, Yellow Sun (nuclear weapon), VMAT, News, NYSE, Safety

MELBOURNE, Fla., May 12, 2023 /PRNewswire/ -- Sun Nuclear, a Mirion Medical company (Mirion, NYSE: MIR), will highlight the latest innovations for Quality Management at the ESTRO Annual Meeting beginning Friday, May 12, in Vienna, Austria. Industry gold standard and novel Radiation Therapy and Diagnostic Imaging QA solutions will be featured in ESTRO booth #150 throughout the meeting, with product demonstrations and user presentations.

Key Points: 
  • MELBOURNE, Fla., May 12, 2023 /PRNewswire/ -- Sun Nuclear , a Mirion Medical company (Mirion, NYSE: MIR), will highlight the latest innovations for Quality Management at the ESTRO Annual Meeting beginning Friday, May 12, in Vienna, Austria.
  • On Sunday, May 14, Sun Nuclear will hold its annual lunch symposium, featuring insights from leaders in the field of Radiation Therapy.
  • Automated, Integrated Quality Management: The SunCHECK Platform powers Quality Management, with centralized, standardized Patient and Machine QA for Radiation Therapy programs.
  • ESTRO attendees will notice new branding reflected in the Sun Nuclear booth and the inclusion of CIRS solutions, which are now part of the Sun Nuclear brand.

More than 50 GenesisCare locations in the U.S. now offer advanced non-surgical treatment option for patients with non-melanoma skin cancer

Retrieved on: 
Thursday, May 11, 2023
Tissue, Extremities, Radiation, Skin, Skin cancer, Cancer, MBA, Smash Mouth, Merkel-cell carcinoma, Scalp, American Society of Clinical Oncology, Journal, MD, Dermatology, Patient, GenesisCare, Risk, Melanoma, NMSC, Metastasis, Sunburn, Recurrence, VMAT, Society, Medical imaging, Dietary supplement, Pharmaceutical industry

This approach can treat multiple skin cancers at the same time, as well as areas likely to form skin cancer in the future.

Key Points: 
  • This approach can treat multiple skin cancers at the same time, as well as areas likely to form skin cancer in the future.
  • Since its launch in March 2021, more than 350 U.S. patients have benefited from the program.
  • Over 3,000 skin patients are treated annually at more than 115 GenesisCare locations across the nation, utilizing this technique as well as more traditional radiation approaches.
  • I feel super confident with my skin now that I have finished my treatment," said David Roe, a GenesisCare patient.

V-SQUARE announces launch of V-Shares MSCI World ESG Materiality and Carbon Transition ETF (VMAT)

Retrieved on: 
Thursday, June 9, 2022
Professional Services, Small Business, Other Professional Services, Human Resources, Finance, Banking, Carbon, Risk management, Quasar, Value, Entrepreneurship, Climate, Cboe Global Markets, ETF, LCT, LLC, ESG, Market share, Decision-making, News, Coal, Policy, Biophysical environment, Multimedia, VMAT, Solution, Sustainability accounting, Listing, Left, MSCI World, Exchange-traded fund, Risk, Prospectus, Ticker, NAV, Industry, Materiality, Muhammad V Square, History, Sustainability Accounting Standards Board, Rationalization, Fund, Social, Social Security Government Pension Offset, Financial adviser, Renewable energy, Bank, Lithium, Security (finance), Share (finance), MSCI, Index

Chicago based V-Square Quantitative Management LLC ( V-Square ), a global asset management firm with sustainability at its core, announced today that it has expanded its market-leading capabilities with the launch of its second thematic ETF the V-Shares MSCI World ESG Materiality and Carbon Transition ETF ( VMAT ).

Key Points: 
  • Chicago based V-Square Quantitative Management LLC ( V-Square ), a global asset management firm with sustainability at its core, announced today that it has expanded its market-leading capabilities with the launch of its second thematic ETF the V-Shares MSCI World ESG Materiality and Carbon Transition ETF ( VMAT ).
  • We are thrilled to launch the V-Shares MSCI World ESG Materiality and Carbon Transition ETF tracking an innovative index, focusing on the financial impacts of sustainability and accounting for current and potential exposure to climate change transition risks and opportunities, said Mamadou-Abou Sarr , Co-Founder and President of V-Square.
  • The V-Shares MSCI World ESG Materiality and Carbon Transition ETF seeks to track the investment results, before fees and expenses, of the MSCI World ESG Materiality and Carbon Transition Select Index (the Underlying Index).
  • The V-Shares MSCI World ESG Materiality and Carbon Transition ETF is distributed by Quasar Distributors, LLC.

American Shared Hospital Services Announces Signing of Joint Venture Agreement for Radiation Therapy Facility in Puebla, Mexico

Retrieved on: 
Friday, April 29, 2022
Pectus carinatum, CMS, Cyprus Securities and Exchange Commission, NYSE, Leeds Gamma Knife Centre, Joint venture, Patient, Monmouth Ocean Hospital Service Corporation, SBRT, GLOBE, AMS, SVP, Annual general meeting, COVID-19, Shareholder, Growth, SAN, Travel, Century, Company, Annual report, Center, Security (finance), JV, IGRT, IMRT, Medical director, Business, Malignancy, Trigeminal neuralgia, Proton therapy, Risk, VMAT, Population, The Center, CA, Airline, Hospital, Medical imaging, Radiosurgery, NewCo

SAN FRANCISCO, CA, April 29, 2022 (GLOBE NEWSWIRE) -- }via NewMediaWire  ‒ American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that it has signed a joint venture agreement to partner in a radiation therapy facility in Puebla, Mexico, located 80 miles from Mexico City.

Key Points: 
  • SAN FRANCISCO, CA, April 29, 2022 (GLOBE NEWSWIRE) -- }via NewMediaWire American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that it has signed a joint venture agreement to partner in a radiation therapy facility in Puebla, Mexico, located 80 miles from Mexico City.
  • Guadalupe Amor Y Bien is a well-established, privately owned radiation therapy facility.
  • The facility, which hasnt operated since 2020, is expected to start up in late 2022/early 2023, pending regulatory approvals.
  • We believe that the joint venture with the principals of the Guadalupe facility is a testament to AMS broadened product line and is ripe with opportunity.

Sun Nuclear Introduces New SaaS Option for its SunCHECK™ Quality Management Platform

Retrieved on: 
Monday, April 11, 2022
Hardware, Other Defense, Data Management, Energy, Technology, Nuclear, Oncology, General Health, Defense, Other Technology, Science, Software, Internet, Health, Research, Cloud, Adoption, Risk, Diagnosis, Analysis, Medical imaging, Patient safety, Product management, NYSE, Radiation, Software as a service, Quality, Amazon (company), Research, Financial condition report, Hospital, Yellow Sun (nuclear weapon), Cancer, GA, U.S. Securities and Exchange Commission, Radiation therapy, Security (finance), Software, MLC, Technology, Securities Exchange Act of 1934, MIR, Time, Amazon Web Services, Architecture, Patient, Result, European Society for Medical Oncology, VMAT, Solution, News, Annual report, QA, Rest, Quality management, Renewable energy, Food delivery

Sun Nuclear Corporation (Sun Nuclear), a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) (Mirion), today announced the release of an enhanced Cloud-hosted, SaaS option for its SunCHECK Quality Management Platform .

Key Points: 
  • Sun Nuclear Corporation (Sun Nuclear), a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) (Mirion), today announced the release of an enhanced Cloud-hosted, SaaS option for its SunCHECK Quality Management Platform .
  • Globally, more than 1,600 clinical users already rely on SunCHECK software for integrated, independent Quality Management of their Radiation Therapy programs.
  • Cloud-hosted, SaaS implementation of the SunCHECK Platform reduces the time and resources required for upfront deployment and ongoing support.
  • SunCHECK users and their IT departments can be assured of reliability, redundancy, and security, with Amazon Web Services as the Cloud provider for the SunCHECK SaaS option.

RaySearch receives large RayStation order in China for carbon ion treatment planning

Retrieved on: 
Monday, December 6, 2021
Carbon, Nasdaq Stockholm, RaySearch Laboratories, NMPA, TCS, CAS, OAS, Ion, Patient, CEO, IMP, Chinese Academy of Sciences, Cancer, GSI Helmholtz Centre for Heavy Ion Research, LTD, EU, VMAT, CET, Neoplasm, IMRT, Institute, Pharmaceutical industry, Medical imaging

STOCKHOLM, Dec. 7, 2021 /PRNewswire/ -- Carbon ion therapy is a highly advanced radiation therapy technique that can be effective for complex tumors which are difficult to treat with conventional methods. The market for carbon ion therapy is gaining momentum in China with several facilities either under construction, or in a planning phase.

Key Points: 
  • RaySearch Laboratories AB (publ) announces a large order for the treatment planning system RayStation* by Lanzhou Ion Therapy Co, LTD, a Chinese manufacturer of accelerator systems for carbon ion therapy
    STOCKHOLM, Dec. 7, 2021 /PRNewswire/ -- Carbon ion therapy is a highly advanced radiation therapy technique that can be effective for complex tumors which are difficult to treat with conventional methods.
  • The market for carbon ion therapy is gaining momentum in China with several facilities either under construction, or in a planning phase.
  • The order includes RayStation licenses for three new carbon ion therapy facilities in China.
  • The full RayStation installation includes modules for both carbon ion pencil beam scanning and for conventional photon therapy planning.